Intensity Therapeutics (INTS) Financials: Revenue & Earnings
INTS$3.29-0.09 -2.57%
$8.89M
Market Cap
-0.66
P/E
1.02
Forward P/E
70
Score
Intensity Therapeutics (INTS) Financials: Revenue & Earnings
INTS price $3.29 -0.09 -2.57%
- Ticker
- INTS
- Price
- $3.29
- Change
- -0.09 -2.57%
- Market cap ?
- $8.89M
- P/E ?
- -0.66
- Forward P/E ?
- 1.02
- Dividend yield ?
- 0.00%
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 70
- Value
- 59
- Quality
- 52
- Growth
- 100
Stocklytics score rationale: value 59, quality 52, growth 100.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the…
Earnings and financials
Intensity Therapeutics, Inc. (INTS) trades at $3.29, with a market cap of $8.89M and a trailing P/E of -0.66. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn